As novelty to our well-established identification workflow, we incorporated matched NAT of the respective CRC primary samples in our analysis, thus allowing for the most accurate possible “control” samples of normal expression of peptide-coding regions. This evidence concerns the gene BRD2 and colorectal carcinoma.